PMID- 33067519
OWN - NLM
STAT- MEDLINE
DCOM- 20210310
LR  - 20210310
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Oct 16
TI  - Gender differences in adverse event reports associated with antidiabetic drugs.
PG  - 17545
LID - 10.1038/s41598-020-74000-4 [doi]
LID - 17545
AB  - Little is known about gender-specific reporting of adverse events (AEs) 
      associated with antidiabetic drugs. This study was to assess the gender-related 
      difference in AEs reporting associated with antidiabetic agents. The number of 
      antidiabetic drug-AE pairs associated was identified using the Korea Adverse 
      Event Reporting System database. Prevalence of diabetes was estimated using the 
      Health Insurance Review and Assessment Service-National Patients Sample database. 
      Reporting rate per 10,000 people was calculated by dividing drug-AE pairs with 
      the number of antidiabetic drug users by gender. Gender difference was presented 
      with risk ratio (reporting rate ratio) of women to men. Antidiabetic 
      agent-associated AEs were more frequently reported by women than men throughout 
      body organs and drug classes. 13 out of 17 system organ class level disorders 
      with significant gender differences were reported more often by women than men. 
      By drug class, gender-specific reporting rates were observed in most of the drug 
      classes, especially in newer classes such as glucagon-like peptide-1 analog 
      (GLP1-RA), sodium glucose co-transporter-2 inhibitor (SGLT2i), and 
      thiazolidinedione (TZD). Looking into preferred term level for each drug class, 
      women dominated the reports of class-specific AEs of newer antidiabetic drugs 
      such as urinary tract/genital infection (all reported by women) in SGLT2i, edema 
      in TZD (risk ratio (RR) 12.56), and hyperglycemia in insulin users (RR 15.35). 
      Gender differences in antidiabetic-associated AE reporting often attributed to 
      women. Explanations for these different report levels by gender should be further 
      investigated.
FAU - Joung, Kyung-In
AU  - Joung KI
AD  - School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 
      Gyeong gi-do, South Korea.
FAU - Jung, Gyu-Won
AU  - Jung GW
AD  - School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 
      Gyeong gi-do, South Korea.
FAU - Park, Han-Heui
AU  - Park HH
AD  - School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 
      Gyeong gi-do, South Korea.
FAU - Lee, Hyesung
AU  - Lee H
AD  - School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 
      Gyeong gi-do, South Korea.
FAU - Park, So-Hee
AU  - Park SH
AD  - School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 
      Gyeong gi-do, South Korea.
FAU - Shin, Ju-Young
AU  - Shin JY
AD  - School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 
      Gyeong gi-do, South Korea. shin.jy@skku.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201016
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Thiazolidinediones)
RN  - AA68LXK93C (2,4-thiazolidinedione)
SB  - IM
MH  - Adult
MH  - *Adverse Drug Reaction Reporting Systems
MH  - Aged
MH  - Aged, 80 and over
MH  - Databases, Factual
MH  - Diabetes Mellitus/*drug therapy
MH  - Female
MH  - Glucagon-Like Peptide-1 Receptor/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*adverse effects
MH  - Insulin/metabolism
MH  - Male
MH  - Middle Aged
MH  - Republic of Korea/epidemiology
MH  - Risk
MH  - *Sex Factors
MH  - Sodium-Glucose Transporter 2 Inhibitors/adverse effects
MH  - Thiazolidinediones/adverse effects
PMC - PMC7567832
COIS- The authors declare no competing interests.
EDAT- 2020/10/18 06:00
MHDA- 2021/03/11 06:00
PMCR- 2020/10/16
CRDT- 2020/10/17 05:28
PHST- 2020/03/31 00:00 [received]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/10/17 05:28 [entrez]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/03/11 06:00 [medline]
PHST- 2020/10/16 00:00 [pmc-release]
AID - 10.1038/s41598-020-74000-4 [pii]
AID - 74000 [pii]
AID - 10.1038/s41598-020-74000-4 [doi]
PST - epublish
SO  - Sci Rep. 2020 Oct 16;10(1):17545. doi: 10.1038/s41598-020-74000-4.